Literature DB >> 24724613

Interleukin-18 as a target for modulation of irinotecan-induced intestinal toxicity: a step towards a better therapeutic index?: Commentary on Lima-Junior et al., Br J Pharmacol 171: 2335-2350.

B G Spyropoulos1.   

Abstract

Entities:  

Keywords:  chemotherapy-induced mucosal injury; diarrhoea; interleukin-18; irinotecan; mucositis

Mesh：

Substances：

Year:  2015        PMID： 24724613      PMCID： PMC4594280          DOI： 10.1111/bph.12719

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


× No keyword cloud information.
  12 in total

Review 1.  Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu.

Authors:  K Nakanishi; T Yoshimoto; H Tsutsui; H Okamura
Journal:  Cytokine Growth Factor Rev       Date:  2001-03       Impact factor: 7.638

Review 2.  Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

Authors:  R H Mathijssen; R J van Alphen; J Verweij; W J Loos; K Nooter; G Stoter; A Sparreboom
Journal:  Clin Cancer Res       Date:  2001-08       Impact factor: 12.531

3.  Influence of chemotherapeutic agents on superoxide anion production by human polymorphonuclear leukocytes.

Authors:  N Hara; Y Ichinose; A Motohiro; T Kuda; H Aso; M Ohta
Journal:  Cancer       Date:  1990-08-15       Impact factor: 6.860

4.  Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumor immune surveillance.

Authors:  F Pagès; A Berger; B Henglein; B Piqueras; C Danel; F Zinzindohoue; N Thiounn; P H Cugnenc; W H Fridman
Journal:  Int J Cancer       Date:  1999-06-21       Impact factor: 7.396

5.  Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.

Authors:  Alexander Stein; Wieland Voigt; Karin Jordan
Journal:  Ther Adv Med Oncol       Date:  2010-01       Impact factor: 8.168

6.  Targeted inhibition of IL-18 attenuates irinotecan-induced intestinal mucositis in mice.

Authors:  R C P Lima-Júnior; H C Freitas; D V T Wong; C W S Wanderley; L G Nunes; L L Leite; S P Miranda; M H L P Souza; G A C Brito; P J C Magalhães; M M Teixeira; F Q Cunha; R A Ribeiro
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

7.  Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis.

Authors:  Richard M Logan; Rachel J Gibson; Joanne M Bowen; Andrea M Stringer; Stephen T Sonis; Dorothy M K Keefe
Journal:  Cancer Chemother Pharmacol       Date:  2007-08-17       Impact factor: 3.333

Review 8.  Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe?

Authors:  Brian K Reuter; Theresa T Pizarro
Journal:  Eur J Immunol       Date:  2004-09       Impact factor: 5.532

9.  Nitric oxide-induced Cl- secretion in isolated rat colon is mediated by the release of thromboxane A2.

Authors:  Hideki Sakai; Tomoyuki Suzuki; Miki Murota; Yuji Takahashi; Noriaki Takeguchi
Journal:  J Physiol       Date:  2002-08-15       Impact factor: 5.182

Review 10.  Chemotherapy-induced and/or radiation therapy-induced oral mucositis--complicating the treatment of cancer.

Authors:  Maddireddy Umameshwar Rao Naidu; Gogula Venkat Ramana; Pingali Usha Rani; Iyyapu Krishna Mohan; Avula Suman; Priyadarshni Roy
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715
View more
  2 in total

1.  Dissecting Target Toxic Tissue and Tissue Specific Responses of Irinotecan in Rats Using Metabolomics Approach.

Authors:  Yiran Yao; Pei Zhang; Jing Wang; Jiaqing Chen; Yong Wang; Yin Huang; Zunjian Zhang; Fengguo Xu
Journal:  Front Pharmacol       Date:  2017-03-10       Impact factor: 5.810

2.  Knockdown of TRIM9 attenuates irinotecan‑induced intestinal mucositis in IEC‑6 cells by regulating DUSP6 expression via the P38 pathway.

Authors:  Wenjun Zhao; Qingming Wang
Journal:  Mol Med Rep       Date:  2021-10-22       Impact factor: 2.952
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.